Optimising heart failure treatment: real-world prescription patterns and guideline adherence in Singapore

The 2022 American Heart Association and the 2021 European Society of Cardiology guidelines for the management of heart failure with reduced ejection fraction advocate for a combination of four drug classes, referred to as quadruple therapy. This includes angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor neprilysin inhibitors; beta-blockers; mineralocorticoid receptor antagonists; and sodium-glucose cotransporter 2 inhibitors. Despite clear recommendations, real-world adherence often falls short. This study examines trends in heart failure treatment in Singapore from 2017 to 2022. A cross-sectional descriptive study was conducted using data from patients with heart failure with reduced ejection fraction across five tertiary care hospitals in Singapore. Administrative records were extracted from the Singapore Cardiovascular Longitudinal Outcomes Database. The analysis included prescription patterns of heart failure therapies, dosage adherence to guideline-recommended target doses, and factors influencing drug choices. Generalized linear mixed models and multinomial logit models were employed to assess determinants of drug prescription. The study included 6,578 patients with a median age of 71 years, 70.2% of whom were male. The majority were of Chinese (62.6%), and the mean left ventricular ejection fraction was 28%. Quadruple therapy increased from 0% in 2017 to 14.5% in 2022. Triple therapy was prescribed in 23.8% of patients in 2022, with the most common combination being an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or angiotensin receptor neprilysin inhibitor, combined with a beta-blocker and a mineralocorticoid receptor antagonist. Dual therapy was used in 23.7%, most frequently an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or angiotensin receptor neprilysin inhibitor, combined with a beta-blocker. However, monotherapy and non-use of any recommended drug remained significant at 25.9% and 12.1%, respectively. Around 80% of patients on angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or angiotensin receptor neprilysin inhibitors and 60% on beta-blockers received less than 50% of the guideline-recommended doses, while 95% of patients on sodium-glucose cotransporter 2 inhibitors received the recommended fixed target dose. Factors associated with lower drug prescription included advanced age, chronic kidney disease, and palliative care. Institutional variations in prescription patterns were also observed. Despite a gradual increase in the uptake of quadruple therapy, its use remains substantially below guideline expectations, highlighting a persistent gap in the implementation of guideline-directed medical therapy in Singapore.

Authors

Institutions

Publication Details

Journal
BMC Health Services Research
Published
2026-11-20
DOI
https://doi.org/10.1186/s12913-026-16204-4
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Optimising heart failure treatment: real-world prescription patterns and guideline adherence in Singapore

Derek John Hausenloy, Doreen Su‐Yin Tan, Yee How Lau, Chun Fan Lee et al.
1 links
BMC Health Services Research
Heart Failure Treatment and Management
article

Optimising heart failure treatment: real-world prescription patterns and guideline adherence in Singapore

Derek John Hausenloy, Doreen Su‐Yin Tan, Yee How Lau, Chun Fan Lee, Mark Y. Chan, Sameera Jayan Senanayake, S. Kularatna, Phoo Pyae Sone Win, Seet Yoong Loh, Chow Weien, Kheng Leng David Sim, Khung-Keong Yeo, Raymond Ching Chiew Wong, Annie Lee, Kelvin Bryan Tan, Nicholas Graves, Audry Shan Yin Lee
article en

Abstract

The 2022 American Heart Association and the 2021 European Society of Cardiology guidelines for the management of heart failure with reduced ejection fraction advocate for a combination of four drug classes, referred to as quadruple therapy. This includes angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor neprilysin inhibitors; beta-blockers; mineralocorticoid receptor antagonists; and sodium-glucose cotransporter 2 inhibitors. Despite clear recommendations, real-world adherence often falls short. This study examines trends in heart failure treatment in Singapore from 2017 to 2022. A cross-sectional descriptive study was conducted using data from patients with heart failure with reduced ejection fraction across five tertiary care hospitals in Singapore. Administrative records were extracted from the Singapore Cardiovascular Longitudinal Outcomes Database. The analysis included prescription patterns of heart failure therapies, dosage adherence to guideline-recommended target doses, and factors influencing drug choices. Generalized linear mixed models and multinomial logit models were employed to assess determinants of drug prescription. The study included 6,578 patients with a median age of 71 years, 70.2% of whom were male. The majority were of Chinese (62.6%), and the mean left ventricular ejection fraction was 28%. Quadruple therapy increased from 0% in 2017 to 14.5% in 2022. Triple therapy was prescribed in 23.8% of patients in 2022, with the most common combination being an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or angiotensin receptor neprilysin inhibitor, combined with a beta-blocker and a mineralocorticoid receptor antagonist. Dual therapy was used in 23.7%, most frequently an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or angiotensin receptor neprilysin inhibitor, combined with a beta-blocker. However, monotherapy and non-use of any recommended drug remained significant at 25.9% and 12.1%, respectively. Around 80% of patients on angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or angiotensin receptor neprilysin inhibitors and 60% on beta-blockers received less than 50% of the guideline-recommended doses, while 95% of patients on sodium-glucose cotransporter 2 inhibitors received the recommended fixed target dose. Factors associated with lower drug prescription included advanced age, chronic kidney disease, and palliative care. Institutional variations in prescription patterns were also observed. Despite a gradual increase in the uptake of quadruple therapy, its use remains substantially below guideline expectations, highlighting a persistent gap in the implementation of guideline-directed medical therapy in Singapore.

BMC Health Services Research
Ministry of Health (SG), National University of Singapore (SG), Changi General Hospital (SG), Tan Tock Seng Hospital (SG), Singapore-HUJ Alliance for Research and Enterprise (SG), National University Heart Centre Singapore (SG), Duke-NUS Medical School (SG), National Heart Centre Singapore (SG), University College London (GB)
Duke-NUS Medical School, National Medical Research Council
Good health and well-being
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon